tbuckley/cabot-search huggingface dataset:
Editorial
Journal: Annals of the Rheumatic Diseases (1952)

The Editorial Committee regret to have to report that the cost of publication of the Annals has risen to a serious degree; this is mainly due to the cost of paper which has twice doubled itself since January, 1951, while the cost of printing has also risen, and the size of the Annals has become substantially greater in the last few numbers.An increase in the annual subscription has already been announced, and the possibility of effecting economies has also had serious consideration.While encfeavouring to continue using the same quality paper for the original scientific articles and illustrations, it will be necessary to use a less expensive paper for the remainder, and to revert to the double-column arrangement for that part of the Journal dealing with the various anti-rheumatic societies and their activities.It is hoped that contributors will endeavour to be brief and to the point, and to remember that while illustrations are helpful, and, indeed, often indispensable, they should not be too numerous.The editors are always loth to cut down papers, but this may prove inevitable if-these suggestions are not borne in mind.The Committee gratefully acknowledge the encouragement and support they have received at all times from the
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
Authors: Ian Mitchell McElree, Ryan L. Steinberg, Sarah L. Mott, Alexander C. Martin, Jordan Richards, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell, Vignesh T. Packiam
Journal: Journal of Clinical Oncology (2022)

497 Background: Bacillus Calmette-Guerin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor (TURBT) for high-risk non-muscle invasive bladder cancer (NMIBC). However, continued BCG production shortages have precluded the use of BCG in many urologic practices. Efficacy of sequential intravesical gemcitabine and docetaxel (Gem/Doce) in the BCG failure setting has been reproduced across multiple institutions. In response to the continuing BCG shortage, Gem/Doce has been utilized at our institution in the BCG-naïve setting. We report the outcomes of a large cohort of patients with high-risk BCG-naïve NMIBC treated with Gem/Doce. Methods: We retrospectively identified all patients with BCG-naïve high-risk NMIBC who were treated with Gem/Doce from May 2013 through April 2021. We included patients with intent to receive 6 weekly intravesical instillations of sequential 1 gram gemcitabine and 37.5mg docetaxel after complete TURBT. Monthly maintenance of 2 years was initiated if disease free at first follow-up. The primary outcome was recurrence-free survival (RFS) and efficacy was evaluated in an intention-to-treat manner. Recurrence was defined as pathologically confirmed tumor relapse in the bladder or prostatic urethra. Progression was defined as T-stage increase from Ta or CIS to T1 or development of muscle invasive or metastatic disease. Survival was assessed using the Kaplan-Meier method and log rank test, indexed from the first Gem/Doce instillation. Results: One hundred seven patients with median follow-up of 15 months were included in the analysis. There were 47 with any CIS, 55 with T1 disease, and 7 with micropapillary variant histology. Four patients did not complete a full induction cycle due to hematuria (3) and severe frequency/nocturia (1). 19 patients sustained a recurrence at any point during follow-up. RFS was 89%, 85%, and 82% at 6, 12, and 24 months, respectively. No difference in RFS was seen in patients with or without CIS (p = 0.42). No patients met criteria for either form of disease progression. One patient underwent cystectomy due to end-stage lower urinary tract symptoms, with final pathology pTisN0. No patients died of bladder cancer. Overall survival was 84% at 24 months. 46 patients reported any symptoms during treatment. Common side effects included urinary frequency/urgency (36%), hematuria (11%), and dysuria (8%). Conclusions: In a large cohort of high-risk, BCG-naïve NMIBC patients, Gem/Doce showed excellent efficacy (84% 2-year HG-RFS). These rates are similar to modern treatment naïve cohorts receiving BCG. Prospective comparative analysis of Gem/Doce in BCG-naïve populations is warranted.[Table: see text]
Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV‐1?
Authors: Elizabeth Calleja, Renate Klein, James Bussel
Journal: American Journal of Hematology (1999)

HTLV-111 (HIV-1) has been shown to be associated with thrombocytopenia of a type resembling immune thrombocytopenic purpura (ITP). HTLV-1 is a retrovirus similar to HIV-l (HTLV-III) in a number of features, such as CD4 tropism. It is responsible for several clinical entities, including adult T-cell leukemia/lymphoma. The relationship, if any, of HTLV-1 and thrombocytopenia has not been systematically studied. To determine how frequently ITP patients are commonly infected with HTLV-1, the following study was performed. Frozen serum samples from 123 randomly selected patients with ITP were thawed and tested for antibodies to HTLV-1 by enzyme-linked immunoabsorbent assay. Positives were confirmed by Western blot. Three patients were initially found to be positive for HTLV-1. One was a female of Caribbean ancestry, one was a male HIV-1+ patient, and one was an adolescent female with no known risk factors for HIV-1. The two females later tested negative for HTLV-1. As a screening program for HTLV-1 antibodies was not introduced into blood banks until November 1988, there may have been passive transfer of the virus from intravenous immunoglobulin that these patients had received. This study of a large number of ITP patients shows that it is extremely unlikely that they are infected with HTLV-1, and, therefore, it is unnecessary to screen ITP patients for seropositivity to HTLV-1. Am. J. Hematol. 61:94–97, 1999. © 1999 Wiley-Liss, Inc.
Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.
Authors: Deniz Tural, Cagatay Arslan, Fatih Selcukbiricik, Omer Fatih Olmez, Mustafa Erman, Yüksel Ürün, Nuri Karadurmus, Emre Akar, Saadettin Kilickap
Journal: Journal of Clinical Oncology (2022)

474 Background: Anti-tumor activity and manageable safety profile of immune checkpoint blockade therapies (ICT) have been demonstrated in previous clinical trials in patients with metastatic urothelial carcinoma. To the best of our knowledge, very limited real-life data is available with the long follow-up time that confirms the durable antitumor activity and safety of ICT. In this study, we reported the real-life results of 56 months follow-up data of urothelial carcinoma patients who were treated with ICT. Methods: Metastatic urothelial carcinoma patients treated with at least one course of ICT included in the study. The primary endpoint was the overall response rate (ORR); secondary endpoints were overall survival (OS), progression-free survival (PFS), duration of the ICT treatment, and safety. Median follow-up, PFS, and OS were estimated by using the Kaplan-Meier method. Results: Data of 185 eligible patients were analyzed, 11.9% of these patients received the ICT as the first line, 76.8 % as the second line, and 11.3 % as the third or more line of treatment. The median age of the patients was 66 years, and 156 (84.3%) were male (37-86). The majority of patients (93.5%) had ECOG PS scores of 0–1 and primary tumor in the bladder was predominant (86.7%). The median follow-up time was 47(1.15-56) months. The complete response rate to ICT, partial response rate, and ORR were 10.3% (n = 19), 19.5% (n = 36), and 29.8% (n = 55), respectively. The median duration of response was 33.1 months (95% CI, 16.5–49.7). Of the fifty-five patients who responded to treatment, 28 (51%) had an ongoing response at the time of the analysis. Median PFS and OS was 3.8 (2.6–5.1) months and 8.9 (6.8–11.1) months, respectively. 56-month PFS and OS rate was 9.2% and 11.4%, respectively. 56-month PFS and OS rate for CR and PR was 56.2% and 20%, respectively. Fifty-nine percent of patients experienced a treatment-related adverse event of any grade, and 32 (17.3%) of patients had a grade 3–4 treatment-related adverse event. Because of treatment-related side effects, treatment was discontinued in 8 (4.3%) patients and adverse event that required systemic steroid use was reported in only 13 (7%) patients. Four patients (2.2%) died due to treatment-related causes. Conclusions: This 56-month analysis of real-world data confirms the durable response and long-term survival with ICT in metastatic urothelial carcinoma patients. The safety profile was consistent with prior reports, and no new safety signals emerged.
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
Authors: Austin Kalirai, Isaiah Joy, Sunita Ghosh, Christian K. Kollmannsberger, Aaron Richard Hansen, Myuran Thana, Jeffrey Graham, Daniel Yick Chin Heng, Vincent Castonguay, Georg A. Bjarnason, Rodney H. Breau, Anil Kapoor, Frederic Pouliot, Lori Wood, Naveen S. Basappa
Journal: Journal of Clinical Oncology (2022)

346 Background: The use of I/N is a proven first-line option for patients with intermediate/poor IMDC prognostic criteria. The use of vascular endothelial growth factor inhibitors such as sunitinib have shown activity in the treatment of ccmRCC, but their effectiveness post I/N needs better characterization. This study aims to demonstrate the efficacy of sunitinib, and other TKI agents post I/N in ccmRCC in a real world setting. Methods: Patients with ccmRCC who had received I/N and were subsequently treated with TKI between Jan 1, 2011 and December 31, 2019 were identified from CKCis. Time to treatment failure (TTF – time from start of first subsequent TKI to discontinuation for any reason) and overall survival (OS) – time from first subsequent TKI to death) were calculated using the Kaplan-Meier method. Cox regression was performed to adjust for IMDC criteria. RECIST criteria was used to determine best overall response (ORR) of TKI radiographically. Results: 64 patients were treated with TKI post I/N. Characteristics and outcomes are listed in the table. Of the second-line TKI patients, 51 received sunitinib, 10 received pazopanib and 3 received other TKI. Reasons for second-line TKI discontinuation are: 28% toxicity, 34% progression, 7% other reasons while 31% remain on treatment. Median follow-up time was 12.9m. ORR for second-line TKI overall and second-line sunitinib was 30.0% and 29.4%, respectively. Conclusions: These data show that TKI are active after I/N in ccmRCC. TTF may underestimate PFS due to the large number of patients discontinuing treatment for toxicity and not progression. Efficacy of second-line TKI post I/N in this dataset is similar that of first-line sunitinib from recent randomized phase III trials, suggesting that there may be no significant loss of TKI activity after having received first-line I/N. Overall, these data support the use of TKI after I/N.[Table: see text]
MOTOR NOTES FOR MEDICAL MEN
Authors: H. M. Buist
Journal: BMJ (1917)

NECESSITY being ever the mother of invention, sLnce I wrote in these pages on the subject of utilization of coal gas as an alternative motor fuel spirits, whiclh are becoming available in ever diminishing quantities, taatters have marched rapidly as regards evolution, and even the production, of new devices for conining the one form of motor fuel in these islands which not experimental and the increasing use of which i4all gain of the Ministry of Munitions, in that the gas produced the greater' the proportion of the necessary residutary prod-ucts for the manufacture of high explosives, and so on.We are now arrived at the fourth licensing the introduction of petrol rationing.medical men do is regarded as of national importance.Therefore there is no question that those who- licenees will seecre renewals of sorts.order, which comes into force on November 1t,specifically permits the usee of petrol or petrol substitute inthe eonvey- ance of a duly qualified medical practitioner or veterinary surgeon while it is being usedby-him the of iis profession."But it is eqaally plain that, amount which it has been possible to allot medical past has been wholly i-nadequate.It is.scarely plain that the amount it will he possible to allot in the future will be still less adequate.This is to under many heads, perhaps the chif of which ari-that great increases have been made 'agri cultural motor machiinery over whiat earlier in the year, with the result thlat 6,000 tractors in this country to-day and there scarcely be fewer than 15,000 available from the year onwards.Hence, a vast extra demand for fuel will arise under this head.It is of an essential nature, brought out by the Premier last week address farmers in regard to the urgency for unprecedented amount of cereals in these year.The second head is the expansion Allied services, including not merely the British, but t1he ambitious American programme also, which is be launched any time from a couple months onwards.Every gallon of motor fuel to operate will harve sea-borne to France and will therefore make demands on the strictly limited though, fortunately, increainng amount of tank-vessel available.
Deaths
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Graves' disease
Authors: A P Weetman
Journal: BMJ (1988)

data show that the most striking improvement was a reduction in deaths from cardiogenic shock.This may well have occurred because of poor matching of the placebo and treatment groups.The treatment group were younger and had a lower prevalence of previous ischaemic heart disease than the placebo group.The idea that intravenous magnesium could be beneficial by causing coronary vasodilatation is interesting, but to our knowledge there are no trials in vivo comparing the use of magnesium with intravenous nitrates.
Author Missing From Byline and Additional Information
Journal: JAMA (2014)

The SIGMA Type 2 Diabetes Consortium; Karol Estrada, PhD; Ingvild Aukrust, PhD; Lise Bjørkhaug, PhD; Noël P. Burtt, PhD; Josep M. Mercader, PhD; Humberto García-Ortiz, PhD; Alicia Huerta-Chagoya, MSc; Hortensia Moreno-Macías, PhD; Geoffrey Walford, MD; Jason Flannick, PhD; Amy L. Williams, PhD; María J. Gómez-Vázquez, BSc; Juan C. Fernandez-Lopez, MSc; Angélica Martínez-Hernández, PhD; Silvia Jiménez-Morales, PhD; Federico Centeno-Cruz, PhD; Elvia Mendoza-Caamal, MD; Cristina Revilla-Monsalve, PhD; Sergio Islas-Andrade, MD, PhD; Emilio J. Córdova, PhD; Xavier Soberón, PhD; María E. González-Villalpando, MD; E. Henderson, MD; Lynne R. Wilkens, DrPH; Loic Le Marchand, MD, PhD; Olimpia Arellano-Campos, MD, PhD; Maria L. Ordóñez-Sánchez, BSc; Maribel Rodríguez-Torres, BSc; Rosario Rodríguez-Guillén, MSc; Laura Riba, MSc; Laeya A. Najmi, MSc; Suzanne B.R. Jacobs, PhD; Timothy Fennell, BSc; Stacey Gabriel, PhD; Pierre Fontanillas, PhD; Craig L. Hanis, PhD; Donna M. Lehman, PhD; Christopher P. Jenkinson, PhD; Hanna E. Abboud, MD; Graeme I. Bell, PhD; Maria L. Cortes, PhD; Michael Boehnke, PhD; Clicerio González-Villalpando, MD; Lorena Orozco, MD, PhD; Christopher A. Haiman, ScD; Teresa Tusié-Luna, MD, PhD; Carlos A. Aguilar-Salinas, MD, PhD; David Altshuler, MD, PhD; Pål R. Njølstad, MD, PhD; Jose C. Florez, MD, PhD; Daniel G. MacArthur, PhD
Chronic Obstructive Pulmonary Disease
Authors: Janet M. Torpy
Journal: JAMA (2010)

Chronic Obstructive Pulmonary DiseaseO ne of the most common lung disorders in adults is chronic obstructive pulmonary disease (COPD), a term used to include chronic bronchitis and emphysema.Obstruction due to airway inflammation and excess mucus occurs in the airways of the lung (called bronchi and bronchioles), leading to decreased air flow.This ultimately results in decreased amounts of oxygen delivered to the body' s tissues.In emphysema, there is also destruction of the alveoli (tiny sacs where oxygen and carbon dioxide exchange takes place).Emphysema and chronic bronchitis may both be present in an individual at the same time.COPD is one of the leading causes of death in developed nations and affects both men and women.Smoking is the cause of COPD in most cases and accounts for 80% to 90% of COPD-related deaths.The June 16, 2010, issue of JAMA includes an article about treatment of COPD.This Patient Page is based on one previously published in the November 26, 2008, issue of JAMA.
Enhancing public trust in COVID-19 vaccination during the 2022 FIFA Men’s World Cup: a call for action
Authors: Mohammad Yasir Essar, Faisal A. Nawaz, Salah Eddine Oussama Kacimi, Selma Nihel Klouche- Djedid, Jaffer Shah, Sherief Ghozy, Edward R. Laskowski
Journal: British Journal of Sports Medicine (2022)
Medical Treatment of Gastric Ulcer
Journal: New England Journal of Medicine (1961)

middle, making of the stomach an hour-glass or conical, with an ulcer an inch long,-if the pressure of food is aggravating this, what can pills and powders do that will permanently stop the hemorrhage?Welcome all efforts for cure of the disease by medicine, but by all means band over the case in adhesions, stretching and dragging on the pylorus, or distention of the stomach, to the surgeon.Let us add to our medical treatment that of the surgeon
The Phosphatides.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DIPG-28. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
Authors: Nundia Louis, Xingyao He, Andrea Plunti, Amanda Saratsis, Rishi Lulla, Jason Fangusaro, Craig Horbinski, Stewart Goldman, David James, Ali Shilatifard, Rintaro Hashizume
Journal: Neuro-Oncology (2017)

INTRODUCTION: Focal radiation therapy has long been and still remains the only treatment option for diffuse intrinsic pontine glioma (DIPG). However, all children who suffer from this inoperable and uniformly fatal cancer show evidence of disease progression within months of completing radiation therapy, especially those who harbor the H3.3K27M mutation. Since chemotherapy does not provide any significant outcome improvement, it is crucial to find a suitable radiosensitizer. Our research has shown that the JMJD3 demethylase inhibitor, GSK-J4, not only exerts potent anti-tumor activity on H3K27M mutant DIPG cells, but also restores methylation while decreasing genes that encode proteins involved in DNA double-strand break (DSB) repair. Our aim is to investigate the hypothesis that GSK-J4 may inhibit radiation-induced DNA repair via chromatin modification, making it a potential radiosensitizing agent. METHODS: We evaluated DNA damage repair via quantitative-PCR (q-PCR), immunocytochemistry of DSB markers γH2AX and 53BP1, and DNA repair assay. MNase digestion was used to analyze nucleosome assembly in cellular chromatin. We are currently conducting western blotting, DNA repair assay, FAIRE-seq and clonogenic survival assays to assess DIPG response to radiation therapy (RT) in combination with GSK-J4. In vivo response to radiation monotherapy and combination of RT + GSK-J4 will be measured by bioluminescence imaging and animal survival studies. RESULTS: qPCR results showed that GSK-J4 significantly reduces DNA DSB repair genes such as PARP1, PARP2, SMARCB1 and BRCA1, in irradiated DIPG cells. Immunocytochemistry results support that GSK- J4 sustains high levels of γH2AX and 53BP1 in irradiated DIPG cells, thereby inhibiting DNA DSB repair. MNase assay indicated that GSK-J4 may cause chromatin compaction which prevents DNA DSB repair. Results from the clonogenic assays, to assess long term effect of GSK-J4 on radiated cells, as well as western blotting, FAIRE-seq and in vivo studies will be reported at the meeting.
Representation of women in editorial boards of infectious disease and microbiology journals—cross-sectional study
Authors: Gida Ayada, Angela Huttner, Shiri Avni-Nachman, Nitzan Karny-Epstein, Sher Matsri, Shira Buchrits, Alaa Atamna, Dafna Yahav, Noam Tau
Journal: Clinical Microbiology and Infection (2022)
Improving the Detection of Asbestos in Cosmetics
Authors: Rita Rubin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal